Full Text Inquiry
ePub [ahead of print] Inquiry Form:

Thank you for your interest in the full text of this ePub article. The full text of this article is not available as yet. Could you please complete and submit the brief EPub full text inquiry form given below and one of our representatives will contact you shortly with details of the article, it's availability, and price on order.

Article Detail:

Gender Disparities on Access to Care and Coronary Disease Management

Mortality decline in women to a lesser extent than in men with coronary artery disease (CAD) has provoked a bigger interest in some already existing dilemmas and questions. Many studies carried out in the past three decades have remained without precise answers and with many challenges in the prevention, diagnosis, treatment and outcome of CAD in women. The meta-analysis and the systematic review conducted in the last years have offered novel approaches to understanding CAD gender disparities in access to care and coronary disease management in women, but women still were more likely to have experienced less favorable short- and long-term outcomes than men did. The reasons for these findings should lie in several known segments in the CAD pathophysiological mechanisms different in women and ultimately leading to a lower quality of care.

Clinical presentation in women, which is often characterized by atypical chest pain and a higher prevalence of non-obstructive CAD when evaluated invasively, places women to the false-negative diagnosis of CAD and influences inadequate access to care. Clinical presentation and diagnostic methods, as well as the appropriate treatment options insufficiently examined in women, need to be better defined. The traditional risk factors and the cardiovascular risk factors unique in women have recently been recognized to have a greater impact on women. However, it is important to note, that even in women with obstructive CAD and typical clinical presentation invasive therapy and pharmacologic therapy is not always implemented as recommended by guidelines as in men. Women are underrepresented in CAD trials and, in current guidelines, gender differences in CAD management have not yet been justified. The underestimation of the risk of CAD in women, followed by its underdiagnosis and undertreatment, might be one of the reasons for a worse prognosis in women in comparison with men.

Journal Title: Current Pharmaceutical Design

Price: $95

Inquiry Form

3 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.